学历及学术经历: 孟凤华教授是苏州大学教授，苏州大学生物医用高分子材料重点实验室骨干成员、全球高被引学者（Clarivate Analytics，2018-2022）、欧洲研究理事会（ERC）Consolidator Grant特聘会评专家（2020年—）、美国控制释放协会（CRS）会员。她于1995年大连理工大学化工学院高分子化工专业获学士学位，1998年中国科学院长春应用化学研究所高分子化学与物理专业获理学硕士学位（导师：黄葆同院士），2003年荷兰屯特大学（University of Twente）高分子化学和生物材料专业获理学博士学位（导师：Jan Feijen教授）。2005-2007年在荷兰屯特大学生物医学技术研究所从事博士后研究。2007年受聘为苏州大学副教授，2010年晋升为教授、博士生导师。 孟凤华教授在国际主流期刊如Adv. Mater.、Angew.Chem.-Int. Edit.、Signal Transduct. Tar.、J. Control. Release、Biomaterials、Bioact. Mater.等上发表了180多篇同行评审文章（引用次数> 22000次，H指数：78），并编撰了三本书的章节。她已申请国内外发明专利> 75件，授权60余件（11件专利已转让）。获得苏州市科技进步奖二等奖和江苏省科技进步奖二等奖各一次；两篇论文获得“中国百篇最具影响国际学术论文”、两次苏州市自然科学优秀学术论文一等奖等奖项。她担任 Drug Delivery and Translational Research、Exploration of Medicine 期刊的编委会成员；还担任过 CRS 2019 年年会组会会委员及 Biomacromolecules（2024 年）和 Frontiers in Pharmacology（2022 年）特刊的客座编辑。
研究领域： 纳米药物、肿瘤靶向治疗、蛋白质和核酸药物的靶向递送、刺激响应性胶束和聚合物体、癌症免疫疗法、生物医用高分子
主持/参与的科研项目： 1. 穿鼻粘膜的囊泡纳米疫苗用于胶质母细胞瘤的免疫调节和长效清除；国家自然科学基金委面上项目，48万元，主持 2. 工程化细胞微颗粒纳米药物可控制备及其肿瘤治疗新技术，国家重点研发计划纳米前沿重点项目149.52万元，参与 3. 巨噬细胞靶向囊泡药物用于自身免疫性疾病的安全高效治疗；国家自然科学基金委重点项目；300万元，主持 4. 放射性药物制剂创新技术，公司合作项目，1000万元，共同主持 5. 抗寄生虫病的纳米药物释放系统；国家自然科学基金委国际合作与交流项目，160万元，主持 6. CT可视和还原响应生物可降解碘化聚合物囊泡用于肺癌筛查和精准靶向治疗；国家自然科学基金委面上项目； 61万元，主持 7. 为成功而塑形：应用于纳米药物的生物可降解聚合物囊泡的最佳形态设计；国家自然科学基金委与荷兰科学研究组织合作研究项目；300万元，主持 8. 基于含DTC的聚碳酸酯共聚物的纳米药物平台制剂技术，公司合作项目，400万元，共同主持 9. 还原敏感可逆交联生物可降解聚合物囊泡用于蛋白质药物的肿瘤靶向释放；国家自然科学基金面上项目，88万元，主持 10. 具不对称膜结构的 pH 敏感可降解智能型聚合物囊泡用于肿瘤高效靶向治疗；国家自然科学基金面上项目，80万元，主持
代表性论文： 1. J.Y. Wang, B.B. Guo, Z.W. Sun, S.S. Zhao, L. Cao, Z.Y. Zhong*, and F.H. Meng*, Polymersomal poly(I:C) self-magnifies anti-tumor immunity by simultaneously inducing immunogenic cell death and systemic immune activation, Adv. Healthcare Mater. 2024,doi.org/10.1002/adhm.202400784. 2. B.B. Guo, Y. Qu, Y.P. Sun, S.S. Zhao, J.D. Yuan, Z.Y. Zhong*, and F.H. Meng*, Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of “cold” triple-negative breast cancer, Bioact. Mater. 2023, 25, 61-72. 3. Y.P. Sun#, Y.J. Sha#, G.H. Cui, F.H. Meng*, Z.Y. Zhong*, Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy, Adv. Drug Deli. Rev. 2023,192,114624. 4. Y.F. Xia#, J.N. An#, J.Y. Li, W.X. Gu, Y.F. Zhang, S.S. Zhao, C.Z. Zhao, Y. Xu*, B. Li, Z.Y. Zhong*, F.H. Meng*, Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia, Bioactive Mater. 2023, 21, 499-510. 5. W.C. Yan, B.B. Guo, Z. Wang, J.T. Yang, Z.Y. Zhong*, and F.H. Meng*, RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors, J. Control. Release. 2023, 4, 304-315. 6. D.W. Ni#, B.B. Guo#, Zhangyan Zhong, Yu Chen, G. Yang, J.T. Yang, Z.Y. Zhong*, and F.H. Meng*, Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts, Acta Biomater. 2023, 170, 228-239. 7. R. Huang, Hong Du. L. Cheng, P.Z. Zhang, F.H. Meng*, Z.Y. Zhong*,Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer, Acta Biomater. 2023, 168, 529-539. 8. R. Huang, F.F. Wang, H. Fu, X.M. Qi, G.Z. Xing, J. Ren*, L. Cheng, F.H. Meng*, Z.Y. Zhong*,Bioresponsive Chimaeric Polymersomes Mediate Sustained and Liver-Specific siRNA Transfection In Vivo, Biomacromolecules 2023, 24 (11), 5353-5363 9. J.J. Wei#, D. Wu#, S.S. Zhao, Y. Shao, Y.F. Xia, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, F.H. Meng*, Z.Y. Zhong*, Immunotherapy of Malignant Glioma by NonInvasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant. Adv.Sci. 2022, 9, 2103689. 10. J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-Mediated Systemic Nanodelivery of Granzyme B and CpG for Synergistic Glioma Immunotherapy.J. Control. Release, 2022, 347,68-77 11. H. Zheng, B.B. Guo,X.Y. Qiu, Y.F. Xia,Y. Qu, L. Cheng*, F.H. Meng*, Z.Y. Zhong*,Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy, Bioact. Mater., 2022, 16, 1-11. 12. J.J. Jiang#, R.X. Wang#, L. Yang, Y.J. Sha, S.S. Zhao, J.X. Guo, D.F. Chen*, Z.Y. Zhong*, F.H. Meng*, IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma xenografts in mice, J. Control. Release. 2022, 350, 460-470. 14. B.B. Guo, J.J. Wei, J.Y. Wang, Y.P. Sun, J.D. Yuan, Z.Y. Zhong*, and F.H. Meng*, CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy,Acta Biomater. 2022, 145, 200-209. 16. Z. Wang, S.S. Zhao, J. Shi, F.H. Meng*, J.D. Yuan,Z.Y. Zhong*, Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics, Acta Biomater. 2022, 138, 443-452. 17. Z. Wang, B.B. Guo, S.J. Yue, S.S. Zhao, F.H. Meng*, Z.Y. Zhong*, HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis.Int. J. Pharm. 2022, 625, 122126. 18. S.P. Cao#, Y.F. Xia#, J.X. Shao, B.B. Guo, Y.Y. Dong, I.A.B. Pijpers, Z.Y. Zhong, F.H. Meng*, L.K.E.A. Abdelmohsen*, D.S. Williams*, and J.C.M. van Hest,* Biodegradable Polymersomes with Structure Inherent Fluorescence and Targeting Capacity for Enhanced Photo-Dynamic Therapy, Angew. Chem. Int. Ed., 2021,60, 17629-17637. 19. Y.F. Xia, J.J. Wei, S.S. Zhao, B.B. Guo, F.H. Meng*, Bert Klumperman, Z.Y. Zhong*, Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Control. Release 2021, 336, 262–273. 20. Y.H. Wei#, Y.P. Sun#, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective Transferrin Coating as a Facile Strategy to Fabricate BBB-Permeable and Targeted Vesicles for Potent RNAi Therapy of Brain Metastatic Breast Cancer in Vivo, J. Control. Release 2021, 337, 521-529. 21. W.X. Gu#, R.B. Qu#, F.H. Meng*, J.J.L.M. Cornelissen, and Z.Y. Zhong*, Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release,2021,337, 571-588. 22. W.X. Gu, F.H. Meng*, and Z.Y. Zhong*, Actively Targeted Nanomedicines for Precision Cancer Therapy: Concept, Construction, Challenges and Clinical Translation J. Control. Release, 2021, 329, 676-695. 24. Z. Wang, S.S. Zhao, W.X. Gu, Y.Y. Dong, F.H. Meng*, J.D. Yuan,Z.Y. Zhong*, Alpha 3 integrin binding peptide-functionalized polymersomes loading PLK1 inhibitor volasertib for dually targeted molecular therapy of ovarian cancer in vivo Acta Biomater. 2021, 124, 348-357. 26. Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J.C.M. van Hest, Z.Y. Zhong,* CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma Xenografts in Mice, J. Controlled Release, 2020, 320, 421-430. 27. C. Zhou#, Y.F. Xia#, Y.H. Wei, L. Cheng*, J.J. Wei, B.B. Guo, F.H. Meng*, S.P. Cao, J.C.M. van Hest, Z.Y. Zhong*, GE11 Peptide-Installed Chimaeric Polymersomes Tailor-Made for High-Efficiency EGFR-Targeted Protein Therapy of Orthotopic Hepatocellular Carcinoma, Acta Biomater. 2020, 113, 512-521. 28. W.X. Gu#, J.N. An#, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.J.L.M. Cornelissen, and Z.Y. Zhong*, CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater.2019, 31, 1904742. 29. Y. Zou#, Y.H. Wei#, Y.P. Sun, J. Bao, F.R. Yao, Z.K. Li, F.H. Meng*, C.H. Hu, G. Storm, Z.Y. Zhong*, Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor, Theranostics 2019, 9 (26), 8061-8072. 30. Y.H. Wei, X.L. Gu, L. Cheng*, F.H. Meng*, G. Storm, Z.Y. Zhong*, Low-Toxicity Transferrin-Guided Polymersomal Doxorubicin for Potent Chemotherapy of Orthotopic Hepatocellular Carcinoma in Vivo, Acta Biomater. 2019, 92, 196-204. 31. Y. Zou, J.J. Wei, Y.F. Xia, F.H. Meng*, J.D. Yuan, Z.Y. Zhong*, Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin, Signal Transduct. Tar.2018, 3: 32. 32. W.J. Yang, Y. F. Xia, Y. Fang, F.H. Meng*, J. Zhang, R. Cheng, C. Deng, Z.Y. Zhong*, Selective cell penetrating peptide-functionalized polymersomes mediate efficient and targeted delivery of methotrexate disodium to human lung cancer in vivo, Adv. Healthc. Mater.2018, 7(7), 1701135. 34. L. Cheng, L. Yang, F.H. Meng*, Z.Y. Zhong*, Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy, Adv. Healthc. Mater.2018, 7, 1800685. 35. W.J. Yang, Y.H. Wei, J. Zhang, Z.Y. Zhong*, F.H. Meng*,Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo, J. Control. Release2018, 290, 141-149. 36. Y. Zou, Y.F. Xia, F.H. Meng*, J. Zhang, Z.Y. Zhong*, GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment, Mol. Pharm. 2018, 15, 3664-3671. 37. Y. Zou#, M. Zheng#, W.J. Yang, F.H. Meng*, K. Miyata, H.J. Kim, K. Kataoka*, Z.Y. Zhong*,Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo, Adv. Mater.2017, 29, 1703285. 38. Y. Zou#, Y.H. Wei#, G.L. Wang, F.H. Meng*, M.Y. Gao, G. Storm, and Z.Y. Zhong*, Nanopolymersomes with an Ultrahigh Iodine Content for High-Performance X-Ray Computed Tomography Imaging In Vivo, Adv. Mater.2017, 29, 1603997. 39. W.J. Yang, Y.F. Xia, Y. Zou, F.H. Meng*, J. Zhang, Z.Y. Zhong*, Bioresponsive chimaeric nano-polymersomes enable targeted and efficacious protein therapy for human lung cancers in vivo, Chem. Mater., 2017, 29, 8757-8765. 40. Y. Fang, W.J. Yang, L. Cheng*, F.H. Meng*, J. Zhang, Z.Y. Zhong*, EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo, Acta Biomater.2017, 64, 323-333. 41. Y. Fang, Y. Jiang, Y. Zou, F.H. Meng*, J. Zhang, C. Deng, H.L. Sun and Z.Y. Zhong*, Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(e-caprolactone) micelles, Acta Biomater. 2017, 50, 396-406. 42. N. Zhang, Y.F. Xia, Y. Zou, W.J. Yang, J. Zhang, Z.Y. Zhong*, and F.H. Meng*, ATN-161 Peptide Functionalized Reversibly Crosslinked Polymersomes Mediate Targeted Doxorubicin Delivery into Melanoma-Bearing C57BL/6 Mice, Mol. Pharm.2017, 14(8), 2538-2547. 43. W.J. Yang, Y. Zou, F.H. Meng*, J. Zhang, R. Cheng, C. Deng, and Z.Y. Zhong*, Efficient and targeted suppression of human lung tumor xenografts in mice with methotrexate sodium encapsulated in all-function-in-one chimaeric polymersomes, Adv. Mater. 2016, 28 (37), 8234-8239. 44. Y.N. Zhong, K. Goltsche, L. Cheng, F. Xie, F.H. Meng*, C. Deng, Z.Y. Zhong*, and R. Haag, Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo, Biomaterials2016, 84, 250-261. 46. Y. Zou, Y. Fang, H. Meng, F.H. Meng*, C. Deng, J. Zhang and Z.Y. Zhong*, Self-Crosslinkable and Intracellularly Decrosslinkable Biodegradable Micelles: A Robust, Simple and Multifunctional Nanoplatform for High-Efficiency Targeted Cancer Chemotherapy, J. Control. Release2016, 244, 326-335. 47. Y.N. Zhong, M. Dimde, D. Stöbener, F.H. Meng*, C. Deng, Z.Y. Zhong*, R. Haag, Micelles with Sheddable Dendritic Polyglycerol Sulfate Shells Show Extraordinary Tumor Targetability and Chemotherapy In Vivo, ACS Appl. Mater. Interfaces 2016, 8, 27530-27538. 48. X. Li, W.J. Yang, Y. Zou, F.H. Meng*, C. Deng, and Z.Y. Zhong*, Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes, J. Control. Release2015, 220, 704-714. 49. Y.N. Zhong, C. Wang, R. Cheng, L. Cheng, F.H. Meng*, Z. Liu*, Z.Y. Zhong*, and R. Haag, cRGD-Directed, NIR-Responsive and Robust AuNR/PEG-PCL Hybrid Nanoparticles for Targeted Chemotherapy of Glioblastoma In Vivo, J. Control. Release 2014, 195, 63-71. 50. Y. Zou, Y. Song, W.J. Yang, F.H. Meng*, H. Y. Liu, and Z.Y. Zhong*, Galactose-Installed Photo-Crosslinked pH-Sensitive Degradable Micelles for Active Targeting Chemotherapy of Hepatocellular Carcinoma in Mice, J. Control. Release 2014, 193, 154-161 51. F.H. Meng, Y.N. Zhong, R. Cheng, C. Deng, Z.Y. Zhong*, pH-Sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances, Nanomedicine, 2014, 9, 487-499 (invited review) 52. H.L. Sun, F.H. Meng*, R. Cheng, C. Deng, Z.Y. Zhong*, Reduction and pH dual-bioresponsive crosslinked polymersomes for efficient intracellular delivery of proteins and potent induction of cancer cell apoptosis. Acta Biomater. 2014, 10, 2159-2168 53. H.L. Sun, F.H. Meng*, R. Cheng, C. Deng, Z.Y. Zhong*, Reduction-Responsive Polymeric Micelles and Vesicles for Triggered Intracellular Drug Release, Antioxidants & Redox Signaling 2014, 21, 755-767 (invited review) 54. W. Chen, P. Zhong, F.H. Meng*, R. Cheng, C. Deng, J. Feijen, and Z.Y. Zhong*, Redox and pH-Responsive Degradable Micelles for Dually Activated Intracellular Anticancer Drug Release, J. Control. Release 2013, 169, 171–179. 55. H.L. Sun, F.H. Meng*, R. Cheng, C. Deng, Z.Y. Zhong*, Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy. Expert Opinion on Drug Delivery 2013, 10, 1109-1022. (invited review) 56. F.H. Meng, R. Cheng, C. Deng, Z.Y. Zhong*, Intracellular Drug Release Nanosystems, Mater. Today 2012, 15, 436-442. (invited review) 57. F.H. Meng, and Z.Y. Zhong*, Polymersomes Spanning from Nano to Micro Scales: Advanced Vehicles for Controlled Drug Delivery and Robust Vesicles for Virus and Cell-Mimicking, J. Phys. Chem. Letters 2011, 2, 1533-1539. (Invited Perspective) 58. G.J. Liu, S.B. Ma, S.K. Li, R. Cheng, F.H. Meng*, H.Y. Liu, Z.Y. Zhong*, The highly efficient delivery of exogenous proteins into cells mediated by biodegradable chimaeric polymersomes, Biomaterials 2010, 31, 7575-7585. 59. W. Chen, F.H. Meng*, R. Cheng, and Z.Y. Zhong*, pH-Sensitive Degradable Polymersomes for Triggered Release of Anticancer Drugs: a Comparative Study with Micelles, J. Control. Release 2010, 142, 40-46. 60. W. Chen, H.C. Yang, R. Wang, R. Cheng, F.H. Meng*, W.X. Wei, and Z.Y. Zhong*, Versatile Synthesis of Functional Biodegradable Polymers by Combining Ring-Opening Polymerization and Postpolymerization Modification via Michael-Type Addition Reaction, Macromolecules 2010, 43, 201–207. 61. H.L. Sun, F.H. Meng*, B.N. Guo, X.Q. Li, R. Cheng, H.Y. Liu, and Z.Y. Zhong*, Shell-sheddable micelles based on dextran-ss-poly(-caprolactone) diblock copolymer for efficient intracellular release of doxorubicin, Biomacromolecules 2010, 11, 848–854. 62. Y.L. Li, L. Zhu, Z.Z. Liu, R. Cheng, F.H. Meng*, J.H. Cui, S.J. Ji, and Z.Y. Zhong*, Reversibly Stabilized Multifunctional Dextran Nanoparticles Efficiently Deliver Doxorubicin into the Nuclei of Cancer Cells, Angew. Chem. Int. Ed. 2009, 48, 9914-9918. 63. H.L. Sun, B.N. Guo, R. Cheng, F.H. Meng*, H.Y. Liu, Z.Y. Zhong*, Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin, Biomaterials 2009, 30, 6358-6366. 64. H.F. Xu, F.H. Meng*, Z.Y. Zhong*, Reversibly crosslinked temperature-responsive nano-sized polymersomes: synthesis and triggered drug release, J. Mater. Chem. 2009, 19: 4183-4190. 65. F.H. Meng, W.E.Hennink, Z.Y. Zhong*, Reduction-Sensitive Polymers and Bioconjugates for Biomedical Applications, Biomaterials 2009, 30, 2180-2198. 66. F.H. Meng, Z.Y. Zhong*, J. Feijen, Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10, 197-209. | |||||
